Table 1.
Patients’ clinical characteristics in fertility-preserving patients (N=90) cohort according to NGS-based molecular classification.
| Variable | Total cohort N=90 (100) | POLE mut 6 (6.7) | MSI-H 5 (5.6) | TP53 wt 78 (86.7) | TP53 abn 1 (1.1) | P value |
|---|---|---|---|---|---|---|
| Age(years) | 31 (22-42) | 36.5 (26-42) | 36 (30-40) | 30 (22-42) | 33 | 0.107 |
| ≥30 | 36 (40.0) | 4 (66.7) | 5 (100.0) | 44 (56.4) | 1 (100.0) | 0.201 |
| BMI(kg/m2) | 24.8 (15.9-40.9) | 26.3 (16.9-29.7) | 26.4 (22.5-30.0) | 24.52 (15.9-40.9) | 35.4 | 0.345 |
| 25-30 | 43 (47.8) | 4 (66.7) | 2 (40.0) | 25 (32.1) | 0 | 0.200 |
| ≥30 | 12 (13.3) | 0 | 1 (20.0) | 10 (12.8) | 1 (100.0) | |
| IR:N(%) | 36 (40.0) | 2 (33.3) | 2 (40.0) | 31 (39.7) | 1 (100.0) | 0.823 |
| MetS:N(%) | 21 (23.3) | 1 (16.7) | 2 (40.0) | 17 (21.8) | 1 (100.0) | 0.247 |
| PCOS:N(%) | 18 (20.0) | 0 | 0 | 18 (23.1) | 0 | 0.458 |
| Hyperlipidemia:N(%) | 56 (62.2) | 2 (33.3) | 3 (60.0) | 50 (64.1) | 1 (100.0) | 0.402 |
| ER expression:N(%) | - | |||||
| Negative | 0 | 0 | 0 | 0 | 0 | |
| Positive | 90 (100.0) | 6 (100.0) | 5 (100.0) | 78 (100.0) | 1 (100.0) | |
| PgR expression:N(%) | - | |||||
| Negative | 0 | 0 | 0 | 0 | 0 | |
| Positive | 90 (100.0) | 6 (100.0) | 5 (100.0) | 78 (100.0) | 1 (100.0) | |
| E2(pmol/L) | 154.0 (2.0-1324.0) | 187.0 (12.5-1324.0) | 155.0 (93.0-423.0) | 153.5 (2.0-1241.0) | 202.0 | 0.936 |
| P(nmol/L) | 1.21 (0.01-48.73) | 1.3 (0.06-3.66) | 0.41 (0.07-5.14) | 1.18 (0.01-48.73) | 2.91 | 0.571 |
| T(nmol/L) | 1.45 (0.01-4.86) | 1.2 (0.66-2.19) | 0.62 (0.03-1.95) | 1.49 (0.01-4.86) | 2.55 | 0.385 |
| CA-125(U/ml) | 18.29 (1.01-261.3) | 15.81 (10.66-51.52) | 13.48 (11.0-62.2) | 19.22 (1.01-261.3) | 47.57 | 0.420 |
| HE4(pmol/L) | 45.6 (24.2-281.0) | 47.1 (40.5-81.7) | 45.2 (27.9-55.5) | 45.6 (24.7-281.0) | 24.2 | 0.268 |
| Therapy | 0.005 | |||||
| MA | 62 (68.9) | 3 (50.0) | 2 (40.0) | 56 (71.8) | 1 (100.0) | |
| MPA | 2 (2.2) | 1 (16.7) | 1 (20.0) | 0 | 0 | |
| LNG-IUS | 3 (3.3) | 1 (16.7) | 1 (20.0) | 1 (1.3) | 0 | |
| MA+LNG-IUS | 4 (4.4) | 0 | 1 (20.0) | 3 (3.8) | 0 | |
| GnRH-a+Letrozole | 19 (21.1) | 1 (16.7) | 0 | 18 (23.1) | 0 | |
| CR rate | ||||||
| 16w | 25 (27.8) | 0 | 0 | 25 (32.1) | 0 | 0.173 |
| 32w | 51 (56.7) | 3 (50.0) | 3 (60.0) | 45 (57.7) | 0 | 0.881 |
| Therapy outcomes | ||||||
| Overall outcomes | |
|
|
|
|
|
| CR | 85 (94.4) | 5 (83.3) | 5 (100.0) | 75 (96.2) | 0 | 0.035 |
| Recurrence | 12 (14.1) | 0 | 3 (60.0) | 9 (12.0) | / | 0.037 |
| Progression | 12 (13.3) | 3 (50.0) | 2 (40.0) | 7 (9.0) | 0 | 0.013 |
| Oncological outcomes at 16weeks | |
|
|
|
|
0.123 |
| CR | 25 (27.8) | 0 | 0 | 25 (32.1) | 0 | |
| NR | 28 (31.1) | 3 (50.0) | 3 (60.0) | 21 (26.9) | 1 (100.0) | |
| PR | 34 (37.8) | 2 (33.3) | 2 (40.0) | 30 (38.5) | 0 | |
| PD | 3 (3.3) | 1 (16.7) | 0 | 2 (2.7) | 0 | |
| Oncological outcomes at 32weeks | 0.325 | |||||
| CR | 56 (62.2) | 4 (66.7) | 3 (60.0) | 49 (62.8) | 0 | |
| NR | 9 (10.0) | 2 (33.3) | 0 | 7 (9.0) | 0 | |
| PR | 22 (24.4) | 0 | 2 (40.0) | 19 (24.4) | 1 (100.0) | |
| PD | 3 (3.3) | 0 | 0 | 3 (3.8) | 0 | |
| Follow-up period(weeks) | 59.8 (19.1-104.0) | 39.4 (26.7-84.3) | 65.7 (49.1-100.4) | 59.9 (19.1-104.0) | 93 | 0.131 |
Values are presented as median (range) or number (%). P-value among different groups was calculated by one-way ANOVA, Kruskal-Wallis, Chi-square, or Fisher’s exact test.
BMI, body mass index; IR, insulin resistance; MetS, metabolic syndrome; PCOS, polycystic ovary syndrome; ER, estrogen receptor; PgR, progesterone receptor; E2, Estradiol; P, Progesterone; T, Testosterone; MA, megestrol acetate; MPA, medroxyprogesterone acetate; LNG-IUS, levonorgestrel intrauterine system; GnRH-a, Gonadotropin-releasing hormone analogues; CR, complete response; NR, no response; PR, partial response; PD, progressive disease; POLE mut, DNA polymerase epsilon mutation; MSI-H, high microsatellite instability; TP53 wt, TP53 wildtype; TP53 abn, TP53 abnormal.